Company Description
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.
Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow’s branded eyecare products.
The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.
Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
| Country | United States |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 315 |
| CEO | Mark Baum |
Contact Details
Address: 102 Woodmont Boulevard, Suite 610 Nashville, Tennessee 37205 United States | |
| Phone | 615 733 4730 |
| Website | harrow.com |
Stock Details
| Ticker Symbol | HROW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001360214 |
| CUSIP Number | 415858109 |
| ISIN Number | US4158581094 |
| Employer ID | 45-0567010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark L. Baum J.D. | Chief Executive Officer and Chairman of the Board |
| Andrew R. Boll C.F.A., C.M.A. | Chief Financial Officer and Corporate Secretary |
| John P. Saharek MBA | Chief Commercial Officer |
| Dr. Dennis E Saadeh Pharm.D. | Chief Scientific Officer |
| Jamie Webb | Director of Communications and Investor Relations |
| Brett A. Burrell | Vice President of Legal and Compliance |
| Kim Barratt | Chief Talent Officer` |
| Dr. Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs and Pharmacovigilance |
| Greg DiPasquale | Senior Vice President and Head of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 17, 2024 | 8-K | Current Report |